Benaroya Research Institute

Seattle, Washington 982101

7 studies enrolling now · 35 studies all time

What they study most

Acute Pancreatitis, Autoantibody Positive, Canakinumab in Type 1 Diabetes, Diabetes Mellitus, Type 1, Diabetes type1, High Risk, Impaired Glucose Tolerance, Local Anesthetic Complication, Local Anesthetic Drug Adverse Reaction, New-onset Type 1 Diabetes Mellitus, Newly Diagnosed Type 1 Diabetes, Non-diabetic Relatives at Risk for Type 1 Diabetes

Studies at this site

• Type 1 Diabetes Extension Study — Recruiting now
• Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus — Recruiting now
• Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics — Recruiting now
• EXtremely Early-onset Type 1 Diabetes EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study) — Recruiting now
• Diabetes RElated to Acute Pancreatitis and Its Mechanisms — Recruiting now
• iMmune SignAtures and Clinical outComes in AP — Recruiting now
• TrialNet Pathway to Prevention of T1D — Recruiting now
• Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D) — Running, not enrolling
• STOP-T1D Low-Dose (ATG) — Stopped early
• Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes — Running, not enrolling
• A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041 — Completed
• Early Markers of Disease and Response to Therapy — Completed
• Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D — Completed
• Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus — Stopped early
• Targeting Beta Cell Dysfunction With Verapamil in Longstanding T1D — Completed
• A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D) — Completed
• Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1D — Completed
• Tocilizumab (TCZ) in New-onset Type 1 Diabetes — Completed
• Defining Normal Postoperative Magnetic Resonance Imaging After Total Knee Arthroplasty — Completed
• Preventing Propofol-associated Injection Pain — Completed
• Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk" — Completed
• Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus (TN20) — Completed
• Effects of Recombinant Human Glutamic Acid Decarboxylase on the Progression of Type 1 Diabetes in New Onset Subjects — Completed
• Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus — Completed
• Canakinumab Study in Individuals With Newly Diagnosed Type 1 Diabetes — Completed
• Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes Mellitus — Completed
• Rituximab in New Onset Type 1 Diabetes — Completed
• New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical Trial — Completed
• ATG-GCSF in New Onset Type 1 Diabetes — Completed
• Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes — Completed
• Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes — Completed
• Proleukin and Rapamune in Type 1 Diabetes — Completed
• Treatment With hOKT3gamma1(Ala-Ala) in T1DM — Stopped early
• Improving Metabolic Assessments in Type 1 Diabetes Mellitus Clinical Trials — Completed
• A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT — Stopped early